EGFR and neoplasm: Recently in pancreatic adenocarcinomas, serine protease inhibitor Kazal type1 (SPINK 1), also called pancreatic secretory trypsin inhibitor (PSTI) and tumour-associated trypsinogen inhibitor (TATI), was shown to activate EGFR [13].